Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops
Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo, Japan (CREDIT: Tomohiro Ohsumi/Bloomberg via Getty Images)
Takeda started the year with a $5.2 billion buyout of Ariad, paying out a huge 74% premium to do a deal that raised more than a few eyebrows in the industry. And now it’s chopping up the company it bought in search of the efficiencies it needs to make the numbers work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.